Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
RVMD
#514
Revolution Medicines, Inc. Common Stock
102.020
0
+0.79%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+0.79%
Aylık değişim
+3.01%
6 aylık değişim
+84.15%
Yıllık değişim
+84.15%
Önceki kapanış
101.220
0
Open
102.020
0
Bid
Ask
Low
102.020
0
High
102.020
0
Hacim
349
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
RVMD
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
168.22 M
185.91 M
186.27 M
186.93 M
193.32 M
198.17 M
—
Valuation ratios
Enterprise value
7.43 B
7.59 B
6.25 B
6.47 B
8.81 B
15.4 B
36.94 B
Price to earnings ratio
-12.32
-12.22
-8.82
-8.14
-8.98
-13.39
-39.32
Price to sales ratio
6 915.56
—
5 246.72
3 688.56
3 511.79
—
—
Price to cash flow ratio
12.6
13.16
10.35
9.64
11.31
16.87
48.17
Price to book ratio
0.99
3.24
0.81
0.84
1.09
9.28
12.02
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.09
-0.08
-0.09
-0.1
-0.14
-0.15
-0.48
Return on equity %
-0.1
-0.09
-0.1
-0.13
-0.19
-0.22
-0.65
Return on invested capital %
-286.23
-309.69
—
—
—
96.88
—
Gross margin %
—
—
100
100
100
100
400
Operating margin %
—
—
-18.99 K
-43.4 K
-50.12 K
-43.31 K
-155.81 K
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
-16.83 K
-40.62 K
-48.52 K
-43.7 K
-149.67 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
14.24
14.2
13.46
11.79
8.05
7.14
40.45
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.78
-0.82
-1.03
-1.18
-1.1
-1.44
-4.75
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
9.29
13.65
11.18
11.33
10.21
10.65
43.37
Net current asset value per share
9.46
13.88
11.35
11.54
10.45
10.91
44.25
Tangible book value per share
8.96
13.08
10.67
9.52
8.07
8.21
36.46
Working capital per share
8.8
12.9
10.5
10.56
9.15
9.39
39.6
Book value per share
9.39
13.5
11.05
9.89
8.44
8.58
37.96
Haberler
瑞银首次覆盖Revolution Medicines股票 因RAS抑制剂潜力给予买入评级
UBS assumes coverage on Revolution stock with buy rating on RAS inhibitor potential
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
Piper Sandler上调Revolution Medicines目标价,看好其药物前景
Piper Sandler raises Revolution stock price target on drug confidence
Needham因成本上升下调Revolution Medicines目标价至145美元
Needham lowers Revolution stock price target to $145 on higher costs
富国银行因临床试验进展上调Revolution Medicines目标价
Wells Fargo raises Revolution stock price target on trial progress
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
并购传闻后财报将至,Revolution Medicines成焦点
Revolution Medicines in spotlight as earnings loom after M&A chatter